NAD+ 500mg · Molecular structure reference
Research reference · Research use only
For research and in vitro use only. Not for human use. UK regulatory framework
Classification of NAD+ 500mg
NAD+ 500mg is documented here as a research peptide, catalogued within the Metabolic Research area. Our listing describes it as "500 mg nicotinamide adenine dinucleotide", which frames the structural family a researcher would reference when planning identity work. Classification at this level is a starting point for documentation only: the amino-acid composition, chain length, and any modifications should be confirmed against primary literature and your institution's reference standards before they inform experimental design. Structural family alone does not establish the identity of a specific lot.
Sequence and notation conventions
Peptide identity is commonly recorded using single-letter or three-letter amino-acid notation together with chain length and any terminal or side-chain modifications. When you transcribe a published sequence for NAD+ 500mg into a laboratory notebook or LIMS entry, retain the source citation alongside the notation so that later readers can trace the representation back to its origin. Consistent notation reduces transcription ambiguity and supports reproducibility across collaborators.
Documenting identity for this batch
Structural overviews never supersede the analytical record for the vial you actually receive. For NAD+ 500mg, rely on the batch documentation supplied with your order — the listing references >98% (HPLC) determined by HPLC, and the accompanying certificate of analysis is the authoritative source for identity and purity of your specific lot. Identity is typically confirmed by orthogonal methods such as HPLC for purity and mass spectrometry for mass confirmation; where a batch CoA lists the methods used, cite those methods rather than a generic structural description when you report your materials.
Why structural verification matters for reproducibility
Reproducible in-vitro work depends on unambiguous material identity. Recording the classification, sequence notation, lot number and catalogue reference (NAD-600MG) for NAD+ 500mg at the point of receipt means downstream results can be tied to a defined, verifiable starting material. This is a methodology practice, not a claim about how the compound behaves: the aim is that another laboratory could, in principle, source an equivalently characterised material and repeat the documented procedure.
Research disclaimer
This reference is provided for laboratory documentation and research-planning context only. It is not therapeutic, diagnostic, dosing, or administration guidance, and it makes no claims of efficacy or safety. AmpouLabs supplies all materials strictly for legitimate in-vitro and analytical research. Researchers remain responsible for evaluating suitability against their own protocols, institutional approvals, and applicable regulations.
Reference material
Batch-documented NAD+ 500mg
View specifications, analytical documentation, and procurement options for this reference listing.
Open product listing